Nabi Biopharmaceuticals (NABI) Reports Q3 Loss of $0.12
Tweet
Share
E-mailGet Alerts NABI Hot Sheet
Price: $1.80 --0%
Financial Fact:
Research and development expenses: 7.6M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Financial Fact:
Research and development expenses: 7.6M
Today's EPS Names:
VIVO, PMCB, PLCE, More
Join SI Premium – FREE
Nabi Biopharmaceuticals (NASDAQ: NABI) reported Q3 EPS of ($0.12), versus ($0.07) reported last year. Revenue for the quarter came in at $632 thousand, versus $1.1 million reported last year.
For earnings history and earnings-related data on Nabi Biopharmaceuticals (NABI) click here.
For earnings history and earnings-related data on Nabi Biopharmaceuticals (NABI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ciena beats estimates on strong AI-driven demand, shares rise
- Duluth Holdings Inc. (DLTH) Tops Q2 EPS by 49c
- Lands' End (LE) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
